Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
Related Questions
How does presence of clinically significant portal hypertension change patient prognosis in MASLD?
How do you incorporate other pharmacologic bariatric/appetite suppressants in the context of their clinical care plan for MASLD?
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
In patients with MASLD and F2–F3 fibrosis, would you initiate Resmetirom even if they are not making active lifestyle changes?
Given that cardiovascular disease is the top cause of morbidity/mortality in patients with MASLD, do you perform any additional screening and/or testing for these patients to minimize this impact?
What clinical, imaging, or serologic markers would be an indication to you to stop GLP-1 therapy for management of MASLD?
What are your biggest takeaways from the MASH-TAG 2025 conference?
In patients with Met-ALD, how do you approach their treatment plan?
